An article in the July 1, 2004, issue of BioWorld Today should not have given an estimate for future sales of Ventavis, a pulmonary arterial hypertension drug being developed by CoTherix Inc., as the company has disavowed previous public projections of the candidate's sales. Also, the article should have said the firm had $42.3 million in cash as of March 31. The article should have stated that CTX-100, a product being developed for emphysema resulting from smoking and genetic emphysema, is scheduled for an additional Phase I study in the second half of this year.

Editor's Note: The correction will be made in BioWorld Online.

No Comments